CCCécile de Chaisemartin

Cécile de Chaisemartin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cécile de Chaisemartin has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of an Enhanced Recovery After Surgery (ERAS) program on the management of complications after laparoscopic or robotic colectomy for cancer

    by Victoria Weets, Hélène Meillat, Jacques Emmanuel Saadoun, Marie Dazza, Cécile de Chaisemartin, Bernard Lelong

    Purpose: Enhanced Recovery After Surgery (ERAS) reduces postoperative complications (POCs) after colorectal surgery; however, its impact on the management of POCs remains unclear. This study compared the diagnosis and management of POCs before and after implementing our ERAS protocol after laparoscopic or robotic colectomy for cancer and examined the short- and mid-term oncologic impacts.Methods: This single-center, retrospective study evaluated all consecutive patients who underwent laparoscopic or robotic colectomy for cancer between 2012 and 2021, focusing on the incidence of POCs within 90 days. We compared outcomes before (standard group) and after (ERAS group) the implementation of our ERAS protocol in January 2016.Results: Significantly fewer patients in the ERAS group developed POCs (standard vs. ERAS, 136 of 380 patients [35.8%] vs.136 of 660 patients [20.6%]; P<0.01). The ERAS group had a significantly shorter mean total length of stay after POCs (13.1 days vs. 11.4 days, P=0.04), and the rates of life-threatening complications (6.7% vs. 0.7%) and 1-year mortality (7.4% vs. 1.5%) were significantly lower in the ERAS group than in the standard group. Among patients with anastomotic complications, laparoscopic reoperation was significantly more common in the ERAS group than in the standard group (8.3% vs. 75.0%, P<0.01). Among patients with postoperative ileus, the diagnosis and recovery times were significantly shorter in the ERAS group than in the standard group, resulting in a shorter total length of stay (13.5 days vs. 10 days, P<0.01).Conclusion: The implementation of an ERAS protocol did not eliminate all POCs, but it did accelerate their diagnosis and management and improved patient outcomes.


  • Open Access

    Piecemeal Resection for Large Colorectal Adenomas Remains Essential in 2022: A Single-Center Experience in a Tertiary French Center

    by Jean-Philippe Ratone, Clément Archimbaud, Alexey Solovyev, Christophe Zemmour, Christian Pesenti, Solène Hoibian, Yanis Dahel, Mariola Marx, Cécile De Chaisemartin, Brice Chanez, et al.

    Background and Aims: Colorectal lesions measuring greater than 20 mm are unsuitable for en bloc endoscopic mucosal resection (EMR): piecemeal EMR (PM-EMR) and endoscopic submucosal dissection (ESD) are needed. The European Society of Gastrointestinal Endoscopy (ESGE) recommends ESD only for microinfiltrative lesions, although Japanese teams perform en bloc ESD for all lesions. We report the outcomes obtained in our endoscopy unit for these lesions and assess the hybrid “knife-assisted piecemeal EMR” (KAPM-EMR) technique. The main aim was to assess the short-term outcomes (C1). The secondary objectives were to evaluate the long-term results (C2), adverse event rate and management of recurrence. Methods: We retrospectively analyzed data from patients treated by PM-EMR, KAPM-EMR and ESD for a colorectal lesion measuring greater than 20 millimeters using prospective inclusion over four years. Results: Data from 167 patients (median age: 70) with a median follow-up of 15.1 months were analyzed after excluding 95 patients. A total of 131 lesions were removed by PM-EMR, 24 by KAPM-EMR and 12 by ESD; 146/167 (87.4%) patients were considered in remission at C1. Recurrence was treated by endoscopy in 20/21 patients (95%); 86/89 (96.6%) were in remission at C2. A total of 16/167 patients developed adverse events, all of whom except one were endoscopically managed. KAPM-EMR was associated with a higher perforation risk (p=0.037). No differences in postoperative bleeding were found among the three groups (p=0.576). Conclusions: Piecemeal resection remains an effective and safe technique for large colorectal adenomas. KAPM-EMR may be useful but should be applied with caution due to the risk of perforation.


  • Supine bottom-up extralevator abdominoperineal excision for anorectal adenocarcinoma is not inferior to standard approach and may be thus safely performed

    by Diane Mège, Cécile de Chaisemartin, Laure Régis-Marigny, Flora Poizat, Hélène Meillat, Christophe Zemmour, Laurence Moureau, Bernard Lelong

    Background Extralevator abdominoperineal excision (APE) for rectal carcinoma has been described in order to improve pathological and oncological results compared to standard APE. To obtain the same oncological advantages as extralevator APE, we have previously described a new procedure starting by a perineal approach: the supine bottom-up APE. Our objective is to compare oncological and surgical outcomes between the supine bottom-up APE and the standard APE. Methods All patients with low rectal adenocarcinoma requiring APE were retrospectively included and divided into 2 groups: supine bottom-up APE (Group A) and standard APE (Group B). Results From 2008 to 2016, 61 patients were divided into Groups A (n = 30) and B (n = 31). Postoperative outcomes and median length of stay were similar between groups. Patients from Group A had a significantly longer distal margin (30 [8–120] vs. 20 [1.5–60] mm, p = 0.04) and higher number of harvested lymph nodes (14.5 [0–33] vs. 11 [5–25], p = 0.03) than those from Group B. Circumferential resection margin involvement was similar between groups (28 vs. 22%, p = 0.6), whereas tumors from Group A were significantly larger and more frequently classified as T4 than those from Group B. Operative time was significantly shorter in Group A (437.5 [285–655] minutes) than in Group B (537.5 [361–721] minutes, p = 0.0009). At the end of follow-up, local recurrence occurred in 7 and 16% of patients from Groups A and B (p = 0.68). Three-year overall and disease-free survival rates were similar between groups (87 vs. 90%, p = 0.62 and 61 vs. 63%, p = 0.88, respectively). Conclusion Our findings suggest that supine bottom-up APE doesn’t impair surgical outcomes, pathological results, overall and disease-free survivals in comparison with standard APE. This new procedure may be thus safely performed and decrease the operative time. Further randomized multicentric studies are required to confirm these results.


  • Open Access

    Is percutaneous destruction of a solitary liver colorectal metastasis as effective as a resection?

    by Ugo Marchese, Héloïse Seux, Jonathan Garnier, Jacques Ewald, Gilles Piana, Bernard Lelong, Cécile De Chaisemartin, Hélène Meillat, Jean-Robert Delpero, Olivier Turrini

    Ugo Marchese, Héloïse Seux, Jonathan Garnier, Jacques Ewald, Gilles Piana, Bernard Lelong, Cécile De Chaisemartin, Hélène Meillat, Jean-Robert Delpero, and Olivier Turrini. Ann Hepatobiliary Pancreat Surg 2021;25:198-205. https://doi.org/10.14701/ahbps.2021.25.2.198


  • Open Access

    Is Piecemeal Endoscopic Resection Acceptable for Early Colorectal Cancers in Certain Situations? A Single-Center French Study

    by Jean-Philippe Ratone, Fabrice Caillol, Christophe Zemmour, Erwan Bories, Christian Pesenti, Sébastien Godat, Solene Hoibian, Cécile De Chaisemartin, Hélène Meillat, Bernard Lelong, et al.

    Background and Aims: The use of endoscopic treatment for early colorectal cancer (ECC) is increasing. The European guidelines suggest performing piecemeal endoscopic resection (pmR) for benign lesions and en bloc resection for ECC, especially for patients with favorable lymph node involvement risk evaluations. However, en bloc resections for lesions larger than two centimeters require invasive endoscopic techniques. Our retrospective single-center study aimed to determine the clinical impact of performing pmR for ECC rather than traditional en bloc resection. Methods: A single-center study was performed between January 2012 and September 2017. All ECC patients were included. The main objective was to evaluate the number of patients who potentially underwent unnecessary surgery due to piecemeal resection. The secondary endpoints were as follows: disease-free survival (DFS), defined as the time from pmR to endoscopic failure (local recurrence not treatable by endoscopy), complication rate, number of patients who did not undergo surgery by default, and factors predictive of outcomes and complications. Results: One hundred and forty-six ECC endoscopically treated patients were included. In total, 85 patients were excluded (71 who underwent en bloc resection, 14 with pending follow-up). Data from 61 patients (33 women and 28 men) were analyzed. Two patients underwent potentially unnecessary surgery [3.28% (0.9%- 11.2%)]. The DFS rate was 87% (75%-93%) at 6 months and 85% [72%-92%] at 12 months. The median follow- up time was 16.5 months (12.4-20.9). Three patients (4.9%) had complications. One patient did not undergo surgery by default. A Paris classification of 0-2c (HR=9.3 (2.4-35.9), p<0.001) and Vienna classification of 5 [HR=16.3 (3.3-80.4), p<0.001] were factors associated with poor DFS. Conclusion: Performing pmR in place of en bloc resection for ECC had a limited impact on patients. If the pathology (especially deep margins) is analyzable, careful monitoring could be acceptable in ECC patients who undergo pmR.


  • Well-Differentiated Papillary Mesothelioma of the Peritoneum: A Retrospective Study from the RENAPE Observational Registry

    by The Renape Network, Guillaume Vogin, Liza Hettal, Jean-Michel Vignaud, Peggy Dartigues, Diane Goere, Gwenaël Ferron, Bruno Heyd, Jean-Marc Bereder, Jean-Jacques Tuech, et al.

    Well-differentiated papillary mesothelioma of the peritoneum (WDPMP) is a rare entity. Questions regarding management are still being debated as no more th


  • Supine Bottom-Up Extralevator Abdominoperineal Excision With Primary Perineal Approach

    by Cécile de Chaisemartin, Diane Mège, Jean Michel Durey, Hélène Meillat, Jean Robert Delpero, Bernard Lelong

    To improve poor oncological outcomes of conventional abdominoperineal excision (APE), an extralevator abdominoperineal excision has been developed. This technique is associated with a larger pelvic floor defect and needs position changing and flap reconstruction, which increase operating time and morbidity without proof of best oncological results. Based on the recent development of transanal approaches for retrograde transanal mesorectal excision, we describe a novel approach for APE by a primary perineal dissection. We report our technique of supine bottom-up cylindrical extralevator APE.Surgical principles are the same as those described for extralevator APE: the mesorectum is not dissected off the levator muscles so as to obtain a cylindrical specimen with no waist effect at the levator level. In this video, the patient is a 50-year-old woman with a very low rectal adenocarcinoma that involved the internal sphincter and intersphincteric space. She received neoadjuvant radiochemotherapy. The patient was installed in lithotomy (supine) position during the procedure with a primary perineal approach and dissection outside of the external anal sphincter and levator muscles. The coccyx can be resected if necessary. An epiploplasty or a flap with the rectus abdominis muscle can fill the pelvic cavity.The resulting cylindrical specimen was a well-differentiated adenocarcinoma ypT3N0M0 with complete mesorectal excision. The circumferential margin was 15 mm.This single approach for extralevator APE is safe and reproducible with poor morbidity and promising pathological results. It may be a good alternative to the prone position procedure, but it needs to be standardized and evaluated. See Video at http://links.lww.com/DCR/A635.


  • Open Access

    Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22)

    by M. Karoui, A. Rullier, C. Mariette, E. Maillard, A. Bardier, F. Poizat, A. Luciani, A. Sarran, J.-L. Legoux, C. De Chaisemartin, et al.

    Background: Neoadjuvant chemotherapy has proven valuable in several tumors, but not in colon cancer (CC). The present randomized phase II trial addressed this issue in patients (pts) with locally advanced CC.


  • Open Access

    A multicentre randomised controlled trial to evaluate the efficacy, morbidity and functional outcome of endoscopic transanal proctectomy versus laparoscopic proctectomy for low-lying rectal cancer (ETAP-GRECCAR 11 TRIAL): rationale and design

    by the French Research Group of Rectal Cancer Surgery (GRECCAR), Bernard Lelong, Cécile de Chaisemartin, Helene Meillat, Sandra Cournier, Jean Marie Boher, Dominique Genre, Mehdi Karoui, Jean Jacques Tuech, Jean Robert Delpero

    Total mesorectal excision is the standard surgical treatment for mid- and low-rectal cancer. Laparoscopy represents a clear leap forward in the management of rectal cancer patients, offering significant improvements in post-operative measures such as pain, first bowel movement, and hospital length of stay. However, there are still some limits to its applications, especially in difficult cases. Such cases may entail either conversion to an open procedure or positive resection margins. Transanal endoscopic proctectomy (ETAP) was recently described and could address the difficulties of approaching the lower third of the rectum. Early series and case-control studies have shown favourable short-term results, such as a low conversion rate, reduced hospital length of stay and oncological outcomes comparable to laparoscopic surgery. The aim of the proposed study is to compare the rate of positive resection margins (R1 resection) with ETAP versus laparoscopic proctectomy (LAP), with patients randomly assigned to each arm. The proposed study is a multicentre randomised trial using two parallel groups to compare ETAP and LAP. Patients with T3 lower-third rectal adenocarcinomas for whom conservative surgery with manual coloanal anastomosis is planned will be recruited. Randomisation will be performed immediately prior to surgery after ensuring that the patient meets the inclusion criteria and completing the baseline functional and quality of life tests. The study is designed as a non-inferiority trial with a main criterion of R0/R1 resection. Secondary endpoints will include the conversion rate, the minimal invasiveness of the abdominal approach, postoperative morbidity, the length of hospital stay, mesorectal macroscopic assessment, functional urologic and sexual results, faecal continence, global quality of life, stoma-free survival, and disease-free survival at 3 years. The inclusion period will be 3 years, and every patient will be followed for 3 years. The number of patients needed is 226. There is a strong need for optimal evaluation of the ETAP because of substancial changes in the operative technique. Assessment of oncological safety and septic risk, as well as digestive and urological functional results, is particularily mandatory. Moreover, benefits of the ETAP technique could be demonstrated in post-operative outcome. ClinicalTrial.gov: NCT02584985 . Date and version identifier: Version n°2 – 2015 July 6.


  • Recommandations pour la pratique clinique Cancer du rectum

    by V. Bridoux, C. De Chaisemartin, L. Beyer, N. Goasguen, C. Sabbagh, N. Guedj, P. Dartigues, A. Bardier